Castration Resistant Prostate Cancer
Pipeline by Development Stage
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 17 trials with date data
Clinical Trials (17)
Total enrollment: 532 patients across 17 trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
SOM230 Ectopic ACTH-producing Tumors
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
OGX-427 in Castration Resistant Prostate Cancer Patients
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
Phase I Trial of Combination of FOLFIRI and SOM 230
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function